<DOC>
	<DOCNO>NCT01959880</DOCNO>
	<brief_summary>The CPG Styles Study design demonstrate safety different style Mentor 's Contour Profile Gel ( CPG ) breast implant woman undergo primary augmentation , primary reconstruction , revision . Safety information rate capsular contracture , rupture infection collect used determine device safety .</brief_summary>
	<brief_title>CPG Styles Study : A Study Safety Contour Profile Gel Breast Implants ( CPG Styles Study )</brief_title>
	<detailed_description>Silicone gel-filled breast implant introduce early sixty wide-scale distribution time Medical Device Amendments Food Drug Cosmetic Act pass 1976 . In 1983 , gel-filled breast implant designate Class III device require pre-market approval . In May 1990 , Food Drug Administration ( FDA ) publish propose request ( 515 ( b ) ) Pre-market Approval Applications ( PMA ) April 1991 publish final request . This final publication put manufacturer gel-filled breast implant notice continue market gel-filled breast implant , PMA due FDA 90 day final publication date . A pre-market approval ( PMA ) Mentor gel-filled breast implant file FDA July 1991 . At FDA General Plastic Surgery Advisory Committee meet November 1991 , committee recommend submission additional information establish safety effectiveness gel-filled breast implant . In January 1992 , FDA Commissioner announce voluntary moratorium sale gel-filled breast implant allow advisory panel time assess additional information . In April 1992 , moratorium lift reconstruction revision subject . Every subject implant part adjunct study , addition offer participation registry gel-filled breast implant subject . In order implant gel-filled implant augmentation , woman enrol IDE clinical trial . In September 2000 Core Gel study begin , lead way November 2006 FDA approval MemoryGel breast implant . The objective CPG Styles Study determine safety different style Mentor 's Contour Profile Gel ( CPG ) breast implant woman undergo breast augmentation , reconstruction , revision . Throughout duration study , patient require follow-up visit 10 week post-surgery every year surgery 10th year study completion . Total subject population : Up 500 new subject , plus 1500 subject roll CPG Continued Access Study continue 10-year follow-up protocol . On September 10th , 2014 , Mentor receive FDA approval CPG Styles 312 , 322 , 323 , 332 . The study close new subject enrollment .</detailed_description>
	<criteria>Subject genetic female , 18 year age old A candidate : Primary breast augmentation ( general breast enlargement ) , Primary breast reconstruction ( trauma , loss breast tissue due mastectomy , malignancy , contralateral postreconstruction symmetry , congenital deformity , include asymmetry ) , Revision surgery ( previous augmentation reconstruction siliconefilled salinefilled implant ) Signs Informed Consent Agrees return device Mentor explant necessary Agrees comply followup procedure , include return followup visit Subject pregnant Has nurse child within three month study enrollment Been implant silicone implant breast implant ( e.g . silicone artificial joint facial implant ) Confirmed diagnosis follow rheumatic disease syndrome : SLE , Sjogren 's syndrome , scleroderma , polymyositis , connective tissue disorder , rheumatoid arthritis , crystalline arthritis , infectious arthritis , spondylarthropathies , inflammatory arthritis , fibromyalgia , chronic fatigue syndrome Currently condition could compromise complicate wound heal ( except reconstruction subject ) Subject Augmentation cohort diagnosis active cancer type . ( Exception lowgrade nonmetastasizing skin cancer ) Infection abscess anywhere body Demonstrates tissue characteristic clinically incompatible implant ( e.g . tissue damage result radiation , inadequate tissue , compromise vascularity ) Possesses condition , treatment condition , opinion investigator and/or consult physician ( ) , may constitute unwarranted surgical risk Anatomic physiologic abnormality could lead significant postoperative adverse event Demonstrates characteristic unrealistic/unreasonable risk involve surgical procedure Premalignant breast disease without subcutaneous mastectomy Untreated inappropriately treat breast malignancy , without mastectomy Are HIV positive Work Mentor study doctor directlyrelated anyone work Mentor study doctor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Augmentation</keyword>
	<keyword>Breast Reconstruction</keyword>
	<keyword>Breast Revision</keyword>
	<keyword>Silicone Gel</keyword>
	<keyword>Contour Profile Gel</keyword>
	<keyword>Siltex</keyword>
	<keyword>CPG Styles</keyword>
</DOC>